231 related articles for article (PubMed ID: 12528814)
1. Transglutaminase cross-links in intranuclear inclusions in Huntington disease.
Zainelli GM; Ross CA; Troncoso JC; Muma NA
J Neuropathol Exp Neurol; 2003 Jan; 62(1):14-24. PubMed ID: 12528814
[TBL] [Abstract][Full Text] [Related]
2. Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3.
Zainelli GM; Dudek NL; Ross CA; Kim SY; Muma NA
J Neuropathol Exp Neurol; 2005 Jan; 64(1):58-65. PubMed ID: 15715085
[TBL] [Abstract][Full Text] [Related]
3. Calmodulin regulates transglutaminase 2 cross-linking of huntingtin.
Zainelli GM; Ross CA; Troncoso JC; Fitzgerald JK; Muma NA
J Neurosci; 2004 Feb; 24(8):1954-61. PubMed ID: 14985437
[TBL] [Abstract][Full Text] [Related]
4. Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells.
Chun W; Lesort M; Tucholski J; Faber PW; MacDonald ME; Ross CA; Johnson GV
Neurobiol Dis; 2001 Jun; 8(3):391-404. PubMed ID: 11442349
[TBL] [Abstract][Full Text] [Related]
5. Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei.
Karpuj MV; Garren H; Slunt H; Price DL; Gusella J; Becher MW; Steinman L
Proc Natl Acad Sci U S A; 1999 Jun; 96(13):7388-93. PubMed ID: 10377424
[TBL] [Abstract][Full Text] [Related]
6. Tissue transglutaminase does not contribute to the formation of mutant huntingtin aggregates.
Chun W; Lesort M; Tucholski J; Ross CA; Johnson GV
J Cell Biol; 2001 Apr; 153(1):25-34. PubMed ID: 11285271
[TBL] [Abstract][Full Text] [Related]
7. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein.
Sieradzan KA; Mechan AO; Jones L; Wanker EE; Nukina N; Mann DM
Exp Neurol; 1999 Mar; 156(1):92-9. PubMed ID: 10192780
[TBL] [Abstract][Full Text] [Related]
8. Tissue transglutaminase is increased in Huntington's disease brain.
Lesort M; Chun W; Johnson GV; Ferrante RJ
J Neurochem; 1999 Nov; 73(5):2018-27. PubMed ID: 10537061
[TBL] [Abstract][Full Text] [Related]
9. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture.
Cooper JK; Schilling G; Peters MF; Herring WJ; Sharp AH; Kaminsky Z; Masone J; Khan FA; Delanoy M; Borchelt DR; Dawson VL; Dawson TM; Ross CA
Hum Mol Genet; 1998 May; 7(5):783-90. PubMed ID: 9536081
[TBL] [Abstract][Full Text] [Related]
10. Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease.
Munsie L; Caron N; Atwal RS; Marsden I; Wild EJ; Bamburg JR; Tabrizi SJ; Truant R
Hum Mol Genet; 2011 May; 20(10):1937-51. PubMed ID: 21355047
[TBL] [Abstract][Full Text] [Related]
11. Pro-apoptotic protein kinase C delta is associated with intranuclear inclusions in a transgenic model of Huntington's disease.
Zemskov EA; Jana NR; Kurosawa M; Miyazaki H; Sakamoto N; Nekooki M; Nukina N
J Neurochem; 2003 Oct; 87(2):395-406. PubMed ID: 14511117
[TBL] [Abstract][Full Text] [Related]
12. Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice.
Yu ZX; Li SH; Nguyen HP; Li XJ
Hum Mol Genet; 2002 Apr; 11(8):905-14. PubMed ID: 11971872
[TBL] [Abstract][Full Text] [Related]
13. Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications.
Karpuj MV; Becher MW; Steinman L
Neurochem Int; 2002 Jan; 40(1):31-6. PubMed ID: 11738470
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of interrupting the binding of calmodulin to mutant huntingtin.
Dudek NL; Dai Y; Muma NA
J Neuropathol Exp Neurol; 2008 Apr; 67(4):355-65. PubMed ID: 18379433
[TBL] [Abstract][Full Text] [Related]
15. A cellular model that recapitulates major pathogenic steps of Huntington's disease.
Lunkes A; Mandel JL
Hum Mol Genet; 1998 Sep; 7(9):1355-61. PubMed ID: 9700187
[TBL] [Abstract][Full Text] [Related]
16. Dopamine D1 receptor-mediated aggregation of N-terminal fragments of mutant huntingtin and cell death in a neuroblastoma cell line.
Robinson P; Lebel M; Cyr M
Neuroscience; 2008 May; 153(3):762-72. PubMed ID: 18403126
[TBL] [Abstract][Full Text] [Related]
17. Nuclear targeting of mutant Huntingtin increases toxicity.
Peters MF; Nucifora FC; Kushi J; Seaman HC; Cooper JK; Herring WJ; Dawson VL; Dawson TM; Ross CA
Mol Cell Neurosci; 1999 Aug; 14(2):121-8. PubMed ID: 10479410
[TBL] [Abstract][Full Text] [Related]
18. Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease.
Petrasch-Parwez E; Nguyen HP; Löbbecke-Schumacher M; Habbes HW; Wieczorek S; Riess O; Andres KH; Dermietzel R; Von Hörsten S
J Comp Neurol; 2007 Apr; 501(5):716-30. PubMed ID: 17299753
[TBL] [Abstract][Full Text] [Related]
19. Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease.
Sapp E; Penney J; Young A; Aronin N; Vonsattel JP; DiFiglia M
J Neuropathol Exp Neurol; 1999 Feb; 58(2):165-73. PubMed ID: 10029099
[TBL] [Abstract][Full Text] [Related]
20. Protein aggregation in Huntington's disease.
Hoffner G; Djian P
Biochimie; 2002 Apr; 84(4):273-8. PubMed ID: 12106904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
